Fructosamine to HbA1c Calculator
Fructosamine to HbA1c Calculator
Estimate HbA1c from serum fructosamine using the one regression that can be named and sourced — Cohen 2003, HbA1c = 0.017 × fructosamine + 1.61. The page publishes the equation, its correlation and the size of the scatter around it, and does not blend it with the other lines in circulation.
Fructosamine to HbA1c
Fructosamine → predicted HbA1cFructosamine 367 µmol/L
Formula
HbA1c (mmol/mol) = (HbA1c % − 2.15) × 10.929
- 0.017 and 1.61
- the slope and intercept of the regression of HbA1c on fructosamine reported by Cohen RM, Holmes YR, Chenier TC and Joiner CH, Diabetes Care 2003;26(1):163–167, in 153 patients with diabetes, r = 0.78
- µmol/L
- the unit the equation requires. A fructosamine in mmol/L must be multiplied by 1000 first, and a glycated albumin result reported as a percentage is a different measurand that this equation does not accept
- NGSP %
- the HbA1c scale the equation produces, calibrated to the Diabetes Control and Complications Trial. The second line converts it to the IFCC mmol/mol scale used across the UK and Europe, using the published master equation
- what the scatter is
- no numeric prediction interval was published — the 95% limits appear in the paper only as dotted lines on a figure. In the same cohort the glycosylation gap, the difference between measured and predicted HbA1c, ran from −3.2 to +5.5 percentage points. That is the honest measure of how far an individual can sit from this line
- what it was built for
- the regression was derived in order to define that gap, not to convert one test into the other. Using it as a converter is a secondary use of a population line, and it inherits all of the population’s scatter
Worked example
Fructosamine 367 µmol/L
0.017 × 367 = 6.239
6.239 + 1.61 = 7.8% (NGSP)
On the IFCC scale: (7.849 − 2.15) × 10.929 = 62 mmol/mol
367 µmol/L was the mean fructosamine of Cohen's 153 patients, whose mean measured HbA1c was 7.9% — a least-squares line passes through its own means, so it had to land near there
An individual patient at this fructosamine could sit several percentage points either side of 7.8%: in that cohort the glycosylation gap, measured HbA1c minus predicted, ran from −3.2 to +5.5 points
The two equations that can be sourced, side by side
| Fructosamine | Cohen 2003 (adults, n = 153) | Kang 2015 (children, n = 74) | Cohen − Kang |
|---|---|---|---|
| 250 µmol/L | 5.86% | 5.27% | +0.59 points |
| 300 µmol/L | 6.71% | 6.30% | +0.41 points |
| 367 µmol/L | 7.85% | 7.68% | +0.17 points |
| 400 µmol/L | 8.41% | 8.36% | +0.05 points |
| 500 µmol/L | 10.11% | 10.42% | −0.31 points |
When fructosamine is used instead of HbA1c
| Situation | Why HbA1c fails | What fructosamine gives you |
|---|---|---|
| Haemoglobinopathy or haemoglobin variant | The variant alters the assay or the glycation site; many methods report a spurious value | A measurement that does not involve haemoglobin at all |
| Recent transfusion | Transfused red cells carry the donor’s glycation history | A window that begins after the transfusion |
| Haemolysis or any shortened red-cell survival | Cells are replaced before they can glycate, so HbA1c reads falsely low | Independence from red-cell lifespan |
| Pregnancy | Red-cell turnover rises and control needs to be judged over weeks, not months | A 2 to 3 week window that can follow a treatment change |
| A treatment change two weeks ago | HbA1c will not have moved yet | Enough turnover to show the effect |
One equation, named, and why the others are not averaged in
Fructosamine is the total glycated protein in serum, most of it glycated albumin. Because albumin turns over in two to three weeks rather than the two to three months of a red cell, fructosamine reports on a much shorter window than HbA1c. That is the entire reason to measure it: in haemoglobinopathy, after transfusion, in haemolysis or any other shortened red-cell survival, and in pregnancy, HbA1c is either unreliable or too slow, and a test that does not involve haemoglobin answers the question instead.
Clinicians naturally want the answer translated back into the scale they think in, and the literature obliges with several mutually inconsistent regression lines. Most of what circulates online is unattributed. One line can be traced to a primary source and this page uses it: Cohen, Holmes, Chenier and Joiner, in Diabetes Care in 2003, regressed HbA1c on fructosamine in 153 patients and reported HbA1c = 0.017 × fructosamine + 1.61 with a correlation of 0.78. That is the equation above, with its slope, its intercept, its sample size and its correlation printed rather than hidden.
Printing them matters because of what the same paper says next. The regression was not built as a converter. It was built so the authors could define a glycosylation gap — the difference between a patient’s measured HbA1c and the HbA1c this line predicts from their fructosamine — and then show that the gap is large, reproducible within a person, and associated with diabetic nephropathy. In that cohort the gap ranged from −3.2 to +5.5 percentage points. No numeric prediction interval was published; the 95% limits appear only as dotted lines on a figure. So the honest statement about the number this page produces is that it is the population average HbA1c for that fructosamine, that individuals depart from it systematically and by several percentage points, and that the departure is itself clinically meaningful rather than noise.
A second equation can also be sourced, and checking it was instructive. A study of 74 Korean children and adolescents with diabetes, 245 paired samples, reported fructosamine = 48.55 × HbA1c − 5.84, which rearranges to HbA1c = (fructosamine + 5.84) ÷ 48.55. A widely read review of an online fructosamine calculator prints that intercept as +45.84 rather than −5.84; at a fructosamine of 367 µmol/L the two versions differ by 0.8 percentage points, and the version in the primary paper is the one that agrees with Cohen. The table above shows both sourced lines across the working range. They are not averaged here and should not be averaged anywhere: the mean of two regressions fitted to different populations, with different assays and different age ranges, estimates nothing in particular.
Whichever line is used, the result is invalid if the protein it depends on is abnormal. A serum albumin below 3.0 g/dL makes fructosamine unreliable, and nephrotic syndrome, protein-losing enteropathy and cirrhosis all lower it independently of glycaemia. A paraproteinaemia or a polyclonal increase in total protein pushes it the other way. Check the albumin before reading a fructosamine, and read a predicted HbA1c as an approximate translation for a clinician’s ear rather than as a measurement.
Frequently asked questions
What is the formula for converting fructosamine to HbA1c?
HbA1c (%) = 0.017 × fructosamine (µmol/L) + 1.61, from Cohen et al., Diabetes Care 2003;26(1):163–167, derived in 153 patients with a correlation of 0.78. A fructosamine of 367 µmol/L gives a predicted HbA1c of 7.8%, or 62 mmol/mol on the IFCC scale.
How accurate is the conversion?
Less accurate than the tidy formula suggests, and the paper it comes from is the reason we know. No numeric prediction interval was published — the 95% limits appear only as a dotted line on a figure — but in the same cohort the difference between measured and predicted HbA1c ranged from −3.2 to +5.5 percentage points. Treat the output as a population average, not as this patient’s HbA1c.
Why are there several different fructosamine-to-HbA1c equations?
Because each was fitted to a different population with a different assay: Cohen’s in 153 mostly adult American patients, Kang’s in 74 Korean children and adolescents, and several unattributed lines in circulation with no traceable source. They disagree by up to about 0.6 percentage points at low fructosamine values. Averaging them would produce a number belonging to no study at all.
When should fructosamine be used instead of HbA1c?
When haemoglobin makes HbA1c unreliable — haemoglobinopathy or a haemoglobin variant, recent transfusion, haemolysis or any shortened red-cell survival — and when the question is about the last two to three weeks rather than the last three months, as in pregnancy or shortly after a treatment change.
What makes a fructosamine result unreliable?
Anything that changes serum protein. A serum albumin below 3.0 g/dL invalidates it; nephrotic syndrome, protein-losing enteropathy and cirrhosis lower it; a raised total protein from myeloma or polyclonal gammopathy raises it. High vitamin C and high bilirubin interfere with some assays.
Can fructosamine be used to diagnose diabetes?
No. It has no accepted diagnostic role and no diagnostic threshold; the diagnostic criteria are written in glucose and HbA1c. Fructosamine is a monitoring test for patients in whom HbA1c cannot be trusted.
Related calculators
References
- Cohen RM, Holmes YR, Chenier TC, Joiner CH. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care. 2003;26(1):163–167.
- Kang DS, Park J, Kim JK, Yu J. Clinical usefulness of the measurement of serum fructosamine in childhood diabetes mellitus. Ann Pediatr Endocrinol Metab. 2015;20(1):21–26.
- Danese E, Montagnana M, Nouvenne A, Lippi G. Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes. J Diabetes Sci Technol. 2015;9(2):169–176.
- ARUP Laboratories. Fructosamine, test 0099012: non-diabetic reference interval 205–285 µmol/L.
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.